Anti-aldosterones save lives in STEMI heart attack patients: ALBATROSS, REMINDER

August 28, 2017

Certain heart attack patients who have ST-segment elevation myocardial infarction (STEMI) are significantly more likely to survive if they are treated immediately with anti-aldosterone-type drugs in addition to standard therapy, according to new research presented at ESC Congress today.

Formerly considered diuretics, mineralocorticoid receptor antagonists (MRAs) "are still underused in routine clinical practice, but our data may hopefully contribute to expanded use of these life-saving and low-cost drugs," said study investigator Prof Farzin Beygui, MD, PhD, from the ACTION Study Group, and Centre Hospitalier Universitaire de Caen, France.

MRAs such as spironolactone and eplerenone can offset the damaging effect of high aldosterone levels - which rise immediately after a heart attack - augmenting the benefits of optimal standard therapy including reperfusion therapy, beta-blockers, dual antiplatelet therapy, statins and ACE inhibitors, explained Prof Beygui.

The study pooled data from the previously published ALBATROSS and REMINDER trials, both of which were underpowered individually to fully assess the impact of MRA regimens.

Although ALBATROSS (Aldosterone Lethal effects Blockade in Acute myocardial infarction Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up) failed to demonstrate the benefit of a spironolactone-based MRA regimen compared to standard therapy alone, it was tested in a mixed group of STEMI and non-STEMI patients. "There was a suggested potential significant mortality reduction in the STEMI subgroup, that was worth investigating further" he explained.

The REMINDER (Randomized, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction) trial only included STEMI patients, and showed that eplerenone added to standard therapy within the first 24 hours, was more effective compared to standard therapy alone in reducing a clinico-biological endpoint.

For the current analysis, Prof Beygui and his team pooled results from the full REMINDER study group and the STEMI subgroup of ALBATROSS.

In total, across the two trials, 2241 patients were randomly assigned to the addition of an MRA to standard therapy (1118 patients) or standard alone (1123 controls).

After a median follow-up of 190 days, there were significantly fewer deaths in the MRA-treated patients compared to controls (0.4 % vs 1.6%, stratified odds ratio 0.22; 95% CI 0.07-0.65, p=0.006).

"The evidence from our analysis is not as strong as from a specifically designed randomised trial, however the reduction of mortality in STEMI supports the use of MRAs in this indication," concluded Prof Beygui. "These findings highlight the need for more studies that are adequately sized and specifically designed to confirm the potentially major clinical benefit associated with these low-cost treatments."

Explore further: Antimineralocorticoids offer no benefit in heart attack patients without heart failure

Related Stories

Antimineralocorticoids offer no benefit in heart attack patients without heart failure

August 30, 2015
Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.

Mineralocorticoid receptor antagonists no benefit post MI

April 19, 2016
(HealthDay)—For patients with post-myocardial infarction (MI) heart failure, mineralocorticoid receptor antagonists (MRAs) do not improve outcome, according to a study published in the April 26 issue of the Journal of the ...

Gender gap in death from heart attack reduces particularly in younger women

August 27, 2017
The gender gap in death from heart attack has reduced over the past two decades particularly in younger women, according to research presented today at ESC Congress. The study in over 50 000 patients found that overall in-hospital ...

Oxygen therapy does not improve survival in patients with heart attack symptoms

August 28, 2017
Oxygen therapy does not improve survival in patients with heart attack symptoms, according to late-breaking research presented today in a Hot Line LBCT Session at ESC Congress and published in the NEJM.

Eplerenone reduces primary endpoint in acute myocardial infarction patients

April 29, 2014
A drug known to reduce mortality rate in patients with heart failure has now been found significantly effective when administered early in patients following an acute (ST elevated) myocardial infarction. This effect,say the ...

ESC Guidelines on ST-segment elevation myocardial infarction published today

August 26, 2017
European Society of Cardiology (ESC) Guidelines on the management of acute myocardial infarction in patients with ST-segment elevation are published online today in European Heart Journal, and on the ESC website.

Recommended for you

Metabolism switch signals end for healing hearts

September 19, 2017
Researchers have identified the process that shuts down the human heart's ability to heal itself, and are now searching for a drug to reverse it.

Beta blockers not needed after heart attack if other medications taken

September 18, 2017
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge ...

Which single behavior best prevents high blood pressure?

September 15, 2017
(HealthDay)—You probably already know that certain healthy lifestyle behaviors can reduce your risk of developing high blood pressure, but is any one behavior more important than the others?

RESPECT trial shows closing a small hole in heart may protect against recurrent stroke

September 13, 2017
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial ...

Study shows so-called 'healthy obesity' is harmful to cardiovascular health

September 11, 2017
Clinicians are being warned not to ignore the increased cardiovascular health risks of those who are classed as either 'healthy obese' or deemed to be 'normal weight' but have metabolic abnormalities such as diabetes.

Statins reduce deaths from heart disease by 28 percent in men with high LDL levels, says longest ever study

September 6, 2017
Previous research has shown the benefit of statins for reducing high cholesterol and heart disease risk amongst different patient populations. However, until now there has been no conclusive evidence from trials for current ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.